In Brief: PDT/Pharmacia & Upjohn
Executive Summary
PDT/Pharmacia & Upjohn: Companies expand collaboration for the light activated therapy SnET2 (tin ethyl etiopurpurin) to ophthalmology uses. The original collaboration, dating from July 1995, covers development of SnET2 for oncology, urology and dermatology uses. PDT is testing the product in Phase I/II trials for advanced age-related macular degeneration...